#OraklOncology, a French #TechBio company using AI and real patient biology to predict how #cancer drugs will perform in clinical trials, today announced a €30 million #SeriesA 🇫🇷 🧬
The #TechBio fundraising environment is changing. As capital becomes more selective, investors are moving beyond #AI buzzwords to focus on companies demonstrating genuine technical #depth, #impact, and #scientificvalue. 🧬🔬